Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, VivoSim Labs's average Revenue per Share Growth Rate was -48.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -53.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of VivoSim Labs was 103.00% per year. The lowest was -63.80% per year. And the median was -26.90% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
VivoSim Labs 3-Year Revenue Growth Rate Related Terms
FRA:4OR vs MTNB, HEPA, CLSDQ: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, VivoSim Labs's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of -53.60% mean?
VivoSim Labs (FRA:4OR) has a 3-Year Revenue Growth Rate of -53.60% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #709 out of 767 companies in the Biotechnology industry, placing it in the top 92.4%.
Is VivoSim Labs' 3-Year Revenue Growth Rate too high?
VivoSim Labs' current 3-Year Revenue Growth Rate is -53.60%. Based on the distribution chart, VivoSim Labs ranks #709 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 3-Year Revenue Growth Rate compare to MTNB and HEPA?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #709 out of 767 companies for 3-Year Revenue Growth Rate. This places VivoSim Labs in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.00, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for VivoSim Labs and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current 3-Year Revenue Growth Rate is -53.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 3-Year Revenue Growth Rate of -53.60%. The stock's GF Value™ is €14.80, compared to a current price of €3.49 — trading 76.4% below its estimated fair value. The current 3-Year Revenue Growth Rate is -53.60%. VivoSim Labs' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 3-Year Revenue Growth Rate is -53.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 76.4% below its estimated GF Value™ of €14.80.
Key valuation signals for FRA:4OR:
3-Year Revenue Growth Rate: -53.60%
GF Value™: €14.80 vs. price of €3.49 (76.4% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
28GF Score
Get the complete analysis for FRA:4OR
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
